Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain

Launched by BEIJING TIANTAN HOSPITAL · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment method called Tender Point Infiltration (TPI) to help relieve severe pain caused by a skin infection known as herpes zoster (commonly called shingles). The researchers want to find out if adding TPI, which involves injecting a local anesthetic and steroids into painful areas, can improve pain relief for patients compared to just using antiviral medications. Participants in the trial will be adults aged 18 to 75 who have had a shingles rash for less than 90 days and are experiencing significant pain.

To be eligible for this trial, patients must have a pain level above a certain threshold and agree to participate. Those with infections at the injection site, severe health issues, a history of drug abuse, or who are pregnant or breastfeeding are not eligible. If you join the study, you can expect to receive either the TPI treatment or standard antiviral therapy, and you will be monitored to see how well the treatment works for your pain. This trial is currently recruiting participants and aims to provide better options for managing shingles-related pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with onset of HZ rash less than 90 days.
• • 2. HZ affected the spinal nerves (cervical/thoracic/lumbar nerve).
• • 3. Aged 18 to 75 years (inclusive).
• • 4. Pain intensity \> 7 cm on a visual analogue scale (VAS 0-10 cm).
• • 5. Agreed to sign the informed consent form.
• Exclusion Criteria:
• • 1. Infection at the puncture site.
• • 2. Poor general situation unable to be treated.
• • 3. A history of abuse of narcotics.
• • 4. Non-compliance or inability to complete the self-evaluation questionnaires.
• • 5. Pregnancy or lactation.